Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
CF Waller, J Möbius, A Fuentes-Alburo - British Journal of Cancer, 2021 - nature.com
Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth
factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab …
factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab …
Subcutaneous trastuzumab: a review in HER2-positive breast cancer
YA Heo, YY Syed - Targeted Oncology, 2019 - Springer
A subcutaneous (SC) formulation of trastuzumab, a potent humanized anti-Human
Epidermal growth factor Receptor 2 (HER2) receptor monoclonal antibody, with a …
Epidermal growth factor Receptor 2 (HER2) receptor monoclonal antibody, with a …
[HTML][HTML] Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
EC Barat, MLE Arrii, A Soubieux-Bourbon… - The Breast, 2023 - Elsevier
Introduction Subcutaneous (SC) drug administration, such as the Herceptin® in an oncology
day hospital reduces the administration time of trastuzumab. In the context of combination …
day hospital reduces the administration time of trastuzumab. In the context of combination …